Overview

Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors

Status:
Completed
Trial end date:
2016-10-10
Target enrollment:
Participant gender:
Summary
RATIONALE: Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as epirubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panobinostat together with epirubicin may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of panobinostat when given together with epirubicin in treating patients with metastatic malignant solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
National Cancer Institute (NCI)
Treatments:
Epirubicin
Panobinostat